BEIJING – In a new sign of the local government’s willingness to control drug costs, the tender authorities in Hunan province have stirred up a controversy and in return received pushback from some prominent national drug manufacturers’ associations.
Hunan Tender Creates Industry Jitters In China
The price slashes were so harsh that industry associations have staged a rare faceoff with authorities, with many worrying that the Hunan drug tender, being the first in the year, may herald a new round of drug price cuts in China.
More from China
More from Focus On Asia
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.